

# Michael J Rogers

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3266412/michael-j-rogers-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131 papers	15,517 citations	59 h-index	124 g-index
138 ext. papers	16,739 ext. citations	7 avg, IF	6.36 L-index

#	Paper	IF	Citations
131	Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. <i>Osteoporosis International</i> , <b>2008</b> , 19, 733-59	5.3	1008
130	Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. <i>Journal of Bone and Mineral Research</i> , <b>1998</b> , 13, 581-9	6.3	898
129	Cellular and molecular mechanisms of action of bisphosphonates. <i>Cancer</i> , <b>2000</b> , 88, 2961-2978	6.4	743
128	Bisphosphonates: from the laboratory to the clinic and back again. <i>Bone</i> , <b>1999</b> , 25, 97-106	4.7	687
127	Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1999</b> , 96, 133-8	11.5	578
126	New insights into the molecular mechanisms of action of bisphosphonates. <i>Current Pharmaceutical Design</i> , <b>2003</b> , 9, 2643-58	3.3	475
125	The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 7829-34	11.5	423
124	Molecular mechanisms of action of bisphosphonates: current status. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6222s-6230s	12.9	393
123	Biochemical and molecular mechanisms of action of bisphosphonates. <i>Bone</i> , <b>2011</b> , 49, 34-41	4.7	359
122	Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. <i>British Journal of Haematology</i> , <b>1997</b> , 98, 665-72	4.5	358
121	Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'F(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. <i>Journal of Bone and Mineral Research</i> , <b>1997</b> , 12, 1358-67	6.3	331
120	Bone remodelling at a glance. <i>Journal of Cell Science</i> , <b>2011</b> , 124, 991-8	5.3	320
119	Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. <i>Nature Genetics</i> , <b>2007</b> , 39, 960-2	36.3	303
118	Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1117, 209-57	6.5	291
117	Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. <i>Journal of Bone and Mineral Research</i> , <b>2000</b> , 15, 1467-76	6.3	283
116	Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. <i>Molecular Pharmacology</i> , <b>2002</b> , 61, 1255-62	4.3	250
115	Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. <i>Nature Communications</i> , <b>2015</b> , 6, 8983	17.4	232

114	Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. <i>American Journal of Human Genetics</i> , <b>2008</b> , 83, 64-76	11	231
113	The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 16511-6	11.5	225
112	Cellular and molecular mechanisms of action of bisphosphonates. <i>Cancer</i> , <b>2000</b> , 88, 2961-78	6.4	222
111	Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. <i>Molecular Pharmacology</i> , <b>1999</b> , 56, 131-40	4.3	218
110	Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 245-50	4.5	214
109	The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 2201-10		210
108	Overview of bisphosphonates. <i>Cancer</i> , <b>1997</b> , 80, 1652-60	6.4	209
107	Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. <i>Bone</i> , <b>2001</b> , 28, 465-73	4.7	205
106	Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. <i>Journal of Bone and Mineral Research</i> , <b>1998</b> , 13, 1668-78	6.3	198
105	Recent advances in understanding the mechanism of action of bisphosphonates. <i>Current Opinion in Pharmacology</i> , <b>2006</b> , 6, 307-12	5.1	195
104	Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. <i>Molecular Pharmacology</i> , <b>2006</b> , 69, 1624-32	4.3	188
103	The pharmacology of bisphosphonates and new insights into their mechanisms of action. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14 Suppl 2, 53-65	6.3	188
102	Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. <i>Bone</i> , <b>2008</b> , 42, 848-60	4.7	186
101	Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 278-88	6.3	174
100	Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 919-30	15.9	164
99	Overview of bisphosphonates. <i>Cancer</i> , <b>1997</b> , 80, 1652-1660	6.4	162
98	Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. <i>Journal of Bone and Mineral Research</i> , <b>1996</b> , 11, 1482-91	6.3	154
97	Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 2950-60	3.3	140

96	Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. <i>Journal of Bone and Mineral Research</i> , <b>2006</b> , 21, 684-94	6.3	140
95	Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 48213-22	5.4	137
94	The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 88-96	6.3	136
93	Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 606-16	6.3	135
92	From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. <i>Calcified Tissue International</i> , <b>2004</b> , 75, 451-61	3.9	126
91	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. <i>Journal of Medicinal Chemistry</i> , <b>2008</b> , 51, 2187-95	8.3	125
90	A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. <i>British Journal of Pharmacology</i> , <b>2010</b> , 160, 762-71	8.6	110
89	The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 239-46	7.5	110
88	Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 224, 863-9	3.4	105
87	Real-time intravital imaging establishes tumor-associated macrophages as the extraskelatal target of bisphosphonate action in cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 35-42	24.4	104
86	Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. <i>Molecular Cancer</i> , <b>2007</b> , 6, 18	42.1	104
85	The regulation of osteoclast function and bone resorption by small GTPases. <i>Small GTPases</i> , <b>2011</b> , 2, 117-130	2.7	103
84	Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. <i>Bone</i> , <b>2001</b> , 29, 336-43	4.7	94
83	Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. <i>European Journal of Pharmaceutical Sciences</i> , <b>1999</b> , 8, 109-18	5.1	94
82	Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. <i>Bone</i> , <b>2005</b> , 37, 349-58	4.7	88
81	Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 835-47	6.3	85
80	Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. <i>Biomedical Applications</i> , <b>1997</b> , 704, 187-95		85
79	The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. <i>Calcified Tissue International</i> , <b>2003</b> , 72, 80-4	3.9	80

78	Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway. <i>Blood</i> , <b>2006</b> , 107, 651-4	2.2	75
77	Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption. <i>Drug Development Research</i> , <b>2002</b> , 55, 210-224	5.1	71
76	The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 3579-92	15.9	71
75	Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 427-35	8.6	68
74	Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. <i>Biochemical and Biophysical Research Communications</i> , <b>1992</b> , 189, 414-23	3.4	68
73	Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. <i>Journal of Bone and Mineral Research</i> , <b>2003</b> , 18, 204-12	6.3	66
72	Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. <i>Journal of Bone and Mineral Research</i> , <b>1994</b> , 9, 1029-39	6.3	58
71	Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake. <i>Pharmaceutical Research</i> , <b>1997</b> , 14, 625-30	4.5	58
70	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. <i>Journal of Medicinal Chemistry</i> , <b>2010</b> , 53, 3454-64	8.3	56
69	The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. <i>Bone</i> , <b>2009</b> , 44, 908-16	4.7	55
68	Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. <i>Life Sciences</i> , <b>1998</b> , 62, PL95-102	6.8	55
67	Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function. <i>Journal of Cellular Physiology</i> , <b>2007</b> , 213, 710-20	7	55
66	Activation of T cells by bisphosphonates. <i>Advances in Experimental Medicine and Biology</i> , <b>2010</b> , 658, 11-20	3.6	54
65	Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 290, 869-73	3.4	52
64	Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. <i>Cell</i> , <b>2021</b> , 184, 1330-1347.e13	47.2	49
63	Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 6861-8	5.4	48
62	The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. <i>Endocrinology</i> , <b>2007</b> , 148, 5761-8	4.8	48
61	Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 475-83	4.5	48

60	Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. <i>Bioconjugate Chemistry</i> , <b>2008</b> , 19, 2308-10	6.3	47
59	A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. <i>Calcified Tissue International</i> , <b>2007</b> , 81, 403-13	3.9	46
58	Development of a postnatal 3-day-old rat model of mild hypoxic-ischemic brain injury. <i>Brain Research</i> , <b>2003</b> , 993, 101-10	3.7	45
57	Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. <i>British Journal of Pharmacology</i> , <b>2012</b> , 165, 2584-97	8.6	42
56	RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. <i>Arthritis Research and Therapy</i> , <b>2009</b> , 11, R58	5.7	41
55	Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. <i>Cancer Research</i> , <b>2008</b> , 68, 8945-53	10.1	39
54	Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behavior. <i>Calcified Tissue International</i> , <b>2013</b> , 93, 526-39	3.9	37
53	The cellular uptake and metabolism of clodronate in RAW 264 macrophages. <i>Pharmaceutical Research</i> , <b>2001</b> , 18, 1550-5	4.5	36
52	Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. <i>Bone</i> , <b>2020</b> , 139, 115493	4.7	34
51	Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry. <i>Biomedical Applications</i> , <b>2000</b> , 738, 395-403		33
50	A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro. <i>Calcified Tissue International</i> , <b>2012</b> , 90, 151-62	3.9	32
49	The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3334-43		31
48	The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 283-6	4.5	31
47	Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. <i>Journal of Organometallic Chemistry</i> , <b>2005</b> , 690, 2679-2687	2.3	28
46	Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 402, 543-8	3.4	27
45	Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. <i>Journal of Cellular and Molecular Medicine</i> , <b>2008</b> , 12, 928-41	5.6	27
44	Oxysterols: From physiological tuners to pharmacological opportunities. <i>British Journal of Pharmacology</i> , <b>2021</b> , 178, 3089-3103	8.6	26
43	Osteoglycin, a novel coordinator of bone and glucose homeostasis. <i>Molecular Metabolism</i> , <b>2018</b> , 13, 30-41	4.8	25

42	Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. <i>Bone</i> , <b>2011</b> , 49, 140-5	4.7	24
41	Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2011</b> , 46, 4820-6	6.8	24
40	Signal peptide mutations in RANK prevent downstream activation of NF- $\kappa$ B. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 1926-38	6.3	24
39	Impaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function. <i>Small GTPases</i> , <b>2011</b> , 2, 131-142	2.7	22
38	A novel method for efficient generation of transfected human osteoclasts. <i>Calcified Tissue International</i> , <b>2007</b> , 80, 132-6	3.9	21
37	Anti-tumour activity of bisphosphonates in human myeloma cells. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 32, 129-38	1.9	21
36	A highly sensitive prenylation assay reveals in vivo effects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton. <i>Small GTPases</i> , <b>2015</b> , 6, 202-11	2.7	20
35	Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases. <i>Immunology and Cell Biology</i> , <b>2016</b> , 94, 994-999	5	20
34	Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 873-875.e6	11.5	19
33	Bisphosphonates--mechanisms of action in multiple myeloma. <i>Acta Oncologica</i> , <b>2000</b> , 39, 829-35	3.2	19
32	. <i>Cancer</i> ,	6.4	
31	Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , <b>2011</b> , 186, 970-971 <sup>†</sup>		15
30	Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. <i>Cancer</i> , <b>2012</b> , 118, 750-60	6.4	13
29	Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1900	8.4	10
28	JBMR anniversary classic. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998). <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 1265-74	6.3	10
27	Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2014</b> , 1841, 569-73	5	9
26	Bisphosphonates and T-cells: New insights into old drugs. <i>BoneKEy Osteovision</i> , <b>2006</b> , 3, 5-13		9
25	Melphalan modifies the bone microenvironment by enhancing osteoclast formation. <i>Oncotarget</i> , <b>2017</b> , 8, 68047-68058	3.3	8

24	The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates. <i>Bone</i> , <b>2011</b> , 49, 111-21	4.7	8
23	Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 322, 228-35	4.7	8
22	Bisphosphonates <b>2002</b> , 1361-XLIII		8
21	Isolation and purification of rabbit osteoclasts. <i>Methods in Molecular Biology</i> , <b>2012</b> , 816, 145-58	1.4	8
20	Lack of protein prenylation promotes NLRP3 inflammasome assembly in human monocytes. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2315-2317.e3	11.5	7
19	CMT3 alters mitochondrial function in murine osteoclast lineage cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 365, 840-5	3.4	7
18	Application of phosphonate and thiophosphate analogues of nucleotides to studies of some enzyme reactions. <i>Heteroatom Chemistry</i> , <b>1991</b> , 2, 163-170	1.2	7
17	The Molecular Mechanisms of Action of Bisphosphonates. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2007</b> , 5, 130-144	2.5	6
16	Bisphosphonates: Mechanisms of Action <b>2008</b> , 1737-1767		5
15	Isolation and purification of rabbit osteoclasts. <i>Methods in Molecular Medicine</i> , <b>2003</b> , 80, 89-99		5
14	Effects of Bisphosphonates on the Inflammatory Processes of Activated Macrophages. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , <b>1999</b> , 144, 321-324	1	4
13	From vesicle to cytosol. <i>ELife</i> , <b>2018</b> , 7,	8.9	4
12	Mechanisms of Action of Bisphosphonates as Inhibitors of Bone Resorption. <i>Medical Intelligence Unit</i> , <b>1996</b> , 147-177		2
11	Cellular and molecular actions of bisphosphonates <b>2015</b> , 615-627		1
10	Bacterial toxins and bone remodelling <b>2005</b> , 147-168		1
9	THE ANTI-RESORPTIVE DRUG CLODRONATE IS METABOLISED TO A NON-HYDROLYSABLE ATP ANALOGUE BY MAMMALIAN CELLS IN VITRO. <i>Biochemical Society Transactions</i> , <b>1996</b> , 24, 562S-562S	5.1	1
8	Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages.. <i>ELife</i> , <b>2021</b> , 10,	8.9	1
7	Bisphosphonates and Bone CellsMolecular Mechanisms <b>2020</b> , 565-578		0

6 Mechanisms of Action of Bisphosphonates **2006**, 323-343

5 The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma. *British Journal of Haematology*, **2000**, 111, 283-286 4.5

4 MOLECULAR STUDIES OF APOPTOSIS INDUCED BY ANTI-RESORPTIVE BISPHOSPHONATE DRUGS. *Biochemical Society Transactions*, **1996**, 24, 568S-568S 5.1

3 Zoledronic Acid Inhibits Protein Prenylation in Plasmacytoma Tumors In Vivo and Enhances Survival in the INA-6 SCID Mouse Model.. *Blood*, **2004**, 104, 3360-3360 2.2

2 Clinical and translational pharmacology of bisphosphonates **2020**, 1671-1687

1 Cellular and molecular actions of bisphosphonates **2022**, 921-942